MNKD Stock - MannKind Corp.

MNKD Stock Chart

MNKD Profile

MannKind Corporation, a prominent biopharmaceutical entity based in Westlake Village, California, specializes in the advancement and commercialization of inhaled therapeutic products targeting endocrine disorders and orphan lung diseases within the United States. Established in 1991, the company focuses on pioneering treatments that offer innovative alternatives for patients suffering from diabetes and hypothyroidism.

One of MannKind's flagship products is Afrezza, an inhaled insulin designed to enhance glycemic control in adults with diabetes, providing a convenient and effective alternative to traditional injection-based therapies. Additionally, the company promotes Thyquidity, a treatment for hypothyroidism, to a diverse range of healthcare providers including adult and pediatric endocrinologists.

MannKind Corporation collaborates extensively within the pharmaceutical industry, exemplified by its partnership with United Therapeutics Corporation to further develop therapeutic solutions. Moreover, the company has forged an agreement with NRx Pharmaceuticals to advance a dry powder formulation of ZYESAMI (aviptadil), a synthetic version of human vasoactive intestinal peptide aimed at mitigating inflammatory conditions and protecting cellular health.

Driven by a commitment to innovation and patient-centric care, MannKind Corporation continues to expand its portfolio of inhaled therapeutic products, leveraging strategic collaborations and cutting-edge research to address unmet medical needs in the realm of endocrine disorders and orphan lung diseases.

MNKD Revenue Chart

MNKD Earnings